(Q37796036)

23 August 2017

The challenge of non-motor symptoms in Parkinson's disease (English)

1 reference

23 August 2017

1 reference

2

Per Odin

1 reference

23 August 2017

1

K Ray Chaudhuri

1 reference

PubMed ID

20887883

23 August 2017

language of work or name

1 reference

1 January 2010

1 reference

Progress in Brain Research

23 August 2017

1 reference

23 August 2017

184

1 reference

23 August 2017

325-341

1 reference

The rate of cognitive decline in Parkinson disease.

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Range of neuropsychiatric disturbances in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Frequency of bowel movements and the future risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Is fatigue an independent and persistent symptom in patients with Parkinson disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Olfactory function in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Parkinson's disease and sleepiness: an integral part of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Sexual function in patients with Parkinson's disease and their partners

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Negative symptoms: the 'pathology' of motivation and goal-directed behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Neural control of the gastrointestinal tract: implications for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Autonomic dysfunction in movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Nocturnal symptom complex in PD and its management

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Non-motor symptoms of Parkinson's disease: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

123I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Clozapine prevents recurrence of psychosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Direct economic impact of Parkinson's disease: A research survey in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Parkinson's disease and sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Pain in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Narcolepsy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Olfaction in neurodegenerative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The influence of fatigue on health-related quality of life in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Fatigue in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Movement disorder emergencies.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The neuropsychiatry of Parkinson's disease and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Olfactory pathogenesis of idiopathic Parkinson disease revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Physical and mental fatigue in Parkinson's disease: epidemiology, pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Abnormal performance on the PD test battery by asymptomatic first-degree relatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Levodopa-induced psychosis: a kindling phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Non-motor symptoms: identification and management

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Apathy in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Painful Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Pathological gambling is linked to reduced activation of the mesolimbic reward system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

The sleep switch: hypothalamic control of sleep and wakefulness

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Increased risk of Parkinson's disease after depression: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Pramipexole, ropinirole, and mania in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Reliability, validity, and clinical correlates of apathy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Neuropsychiatric non-motor aspects of Parkinson’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Incidental Lewy body disease in a patient with REM sleep behavior disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Prospective study of phobic anxiety and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984017-8

7 January 2021

10.1016/S0079-6123(10)84017-8

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20887883